Faecal tumor M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer? First results of a multicentre study;Pyruvatkinase typ M2 (M2-PK) im stuhl - Ein valider screeningparameter für kolorektale neoplasien? Erste ergebnisse einer multizentrischen vergleichsstudie

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 34-35, 2004, Pages 1806-1807

  Naumann, M ^a   Schaum, B ^a   Oremek, G M ^b   Hanisch, E ^c   Rosch W ^d   Mossner J ^e   Caspary, W F ^a   Stein, J ^a,b  

^a Diakoniekrankenhaus Henriettenstiftung GGmbH   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Asklepiosklinik Dreieich Langen ^*  (Germany)

^d KRANKENHAUS NORDWEST   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; K RAS PROTEIN; PROTEIN P53; PYRUVATE KINASE;

ARTICLE; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; ONCOGENE K RAS; TUMOR SUPPRESSOR GENE; ADENOMA; CLINICAL TRIAL; COLON POLYP; COLORECTAL TUMOR; COMPARATIVE STUDY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DYSENTERY; ENZYMOLOGY; FECES; MASS SCREENING; METHODOLOGY; MULTICENTER STUDY; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; STANDARD; ULCERATIVE COLITIS;

ADENOMA; COLITIS, ULCERATIVE; COLONIC POLYPS; COLORECTAL NEOPLASMS; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; DYSENTERY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; MALE; MASS SCREENING; OCCULT BLOOD; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY;

EID: 4444281174     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829033     Document Type: Article

References (11)

1. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. Brit Med J 1994; 308: 1552
2. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. Brit Med J 1994; 309: 102
3. Eickhoff A, Riemann JF. Colon carcinoma: early detection and endoscopic prevention. Internist 2000; 41: 860-867
4. Gabrielsson N, Granqvist S, Nilsson B. Guaiac tests for detection of occult faecal blood loss in patients with endoscopically verified colonic polyps. Scand J Gastroenterol 1985; 20: 978-982
5. Hardt PD, Toepler M, Ngoumou B et al. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23: 851-853
6. Macrae FA, St John DJ. Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82: 891-898
7. Mazurek S, Grimm H, Boschek CB et al. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Brit J Nutr 2002; 87 (Suppl 1): S23-S29
8. Oremek GM, Muller R, Sapoutzis N et al. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases. Anticancer Res 2003; 23: 1131-1134
9. Pox C, Schulmann K, Schmiegel W. Conventional and molecular screening (fecal tests). Internist 2003; 44: 287-293
10. Starkey BJ. Screening for colorectal cancer. Ann Clin Biochem 2002; 39: 351-365
11. Towler B, Irwig L, Glasziou P et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. Brit Med J 1998; 317: 559-565